Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: A case series

Journal of Child and Adolescent Psychopharmacology

Volumn 6, Issue 3, 1996, Pages 165-175

  Findling, Robert L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG COMBINATION; FEMALE; HUMAN; HYPERACTIVITY; MALE;

EID: 0029851669     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.1996.6.165     Document Type: Article

References (47)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington (DC), American Psychiatric Association, 1987
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington (DC), American Psychiatric Association, 1994
3. Anderson JC, Williams S, McGee R, Silva PA: DSM-III disorders in preadolescent children: Prevalence in a large sample from the general population. Arch Gen Psychiatry 44:69-76, 1987
4. Barkley RA, Fischer M, Edelbrock CS, Smallish L: The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 29:546-557, 1990
5. Barrickman L, Noyes R, Kuperman S, Schumacher E, Verda M: Treatment of ADHD with fluoxetine: A preliminary trial. J Am Acad Child Adolesc Psychiatry 30:762-767, 1991
6. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS: A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 28:777-784, 1989
7. Biederman J, Faraone SV, Keenan K, Benjamin J, Krifcher B, Moore C, Sprich-Buckminster S, Ugaglia K, Jellinek MS, Steingard R, Spencer T, Norman D, Kolodny R, Kraus I, Perrin J, Keller MB, Tsuang MT: Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder: Patterns of comorbidity in probands and relatives in psychiatrically and pediatrically referred samples. Arch Gen Psychiatry 49:728-738, 1992
8. Biederman J, Faraone SV, Spencer T, Wilens T, Norman D, Lapey KA, Mick E, Lehman BK, Doyle A: Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 150:1792-1798, 1993
9. Bird HR, Canino G, Rubio-Stipec M, Gould MS, Ribera J, Sesman M, Woodbury M, Huertas-Goldman S, Pagan A, Sanchez-Lacay A, Moscoso M: Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico: The use of combined measures. Arch Gen Psychiatry 45:1120-1126, 1988
10. Boulos C, Kutcher S, Gardner D, Young E: An open naturalistic trial of fluoxetine in adolescents and young adults with treatment-resistant major depression. J Child Adolesc Psychopharmacol 2:103-111, 1992
11. Bussing R, Levin GM: Methamphetamine and fluoxetine treatment of a child with attention-deficit hyperactivity disorder and obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 3:53-58, 1993
12. Casat CD, Pleasants DZ, Schroeder DH, Parler DW: Bupropion in children with attention deficit disorder. Psychopharmacol Bull 25:198-201, 1989
13. Colle LM, Bélair JF, DiFeo M, Weiss J, LaRoche C: Extended open-label fluoxetine treatment of adolescents with major depression. J Child Adolesc Psychopharmacol 4:225-232, 1994
14. DeVane CL: Pharmacokinetics of the newer antidepressants: Clinical relevance. Am J Med 97 (Suppl 6A):13S-23S, 1994
15. Dunbar GC, Claghorn JL, Kiev A, Rickels K, Smith WT: A comparison of paroxetine and placebo in depressed outpatients. Acta Psychiatr Scand 87:302-305, 1993
16. Emslie GJ, Kowatch R, Costello L, Travis G, Pierce L: Double-blind study of fluoxetine in depressed children and adolescents. Presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New Orleans (LA), October 1995
17. Frankenburg FR, Kando JC: Sertraline treatment of attention deficit hyperactivity disorder and Tourette's syndrome [Letter]. J Clin Psychopharmacol 14:359-360, 1994
18. Gammon GD, Brown TE: Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol 3:1-10, 1993
19. Geller B, Cooper TB, Graham DL, Fetner HH, Marsteller FA, Wells JM: Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder. J Am Acad Child Adolesc Psychiatry 31:34-44, 1992
20. Gittelman R, Mannuzza S, Shenker R, Bonagura N: Hyperactive boys almost grown up: I. Psychiatric status. Arch Gen Psychiatry 42:937-947, 1985
21. Gram LF: Fluoxetine. N Eng J Med 331:1354-1361, 1994
22. Gupta S, Ghaly N, Dewan M: Augmenting fluoxetine with dextroamphetamine to treat refractory depression. Hosp Community Psychiatry 43:281-283, 1992
23. Jain U, Birmaher B, Garcia M, Al-Shabbout M, Ryan N: Fluoxetine in children and adolescents with mood disorders: A chart review of efficacy and adverse effects. J Child Adolesc Psychopharmacol 2:259-265, 1992
24. Jensen PS, Elliott GR (eds): Why don't antidepressants seem to work for depressed adolescents? [Special Section]. J Child Adolesc Psychopharmacol 2:7-45, 1992
25. Kapur S, Mieczkowski T, Mann JJ: Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 268:3441-3445, 1992
26. Kashani JH, Beck NC, Hoeper EW, Fallahi C, Corcoran CM, McAllister JA, Rosenberg TK, Reid JC: Psychiatric disorders in a community sample of adolescents. Am J Psychiatry 144:584-589, 1987
27. Kashani JH, Carlson GA: Seriously depressed preschoolers. Am J Psychiatry 144:348-350, 1987
28. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the national comorbidity survey. Arch Gen Psychiatry 51:8-19, 1994
29. Linet LS: Treatment of a refractory depression with a combination of fluoxetine and D-amphetamine [Letter]. Am J Psychiatry 146:803-804, 1989
30. Mann HB, Greenspan SI: The identification and treatment of adult brain dysfunction. Am J Psychiatry 133:1013-1017, 1976
31. Manuzza S, Klein RG, Bessler A, Malloy P, LaPadula M: Adult outcome of hyperactive boys: Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 50:565-576, 1993
32. McConville BJ, Minnery KL, Sorter MT, West SA, Friedman LM, Christian K: An open study of the effects of sertraline on adolescent major depression. J Child Adolesc Psychopharmacol 6:41-51, 1996
33. Puig-Antich J, Perel JM, Lupatkin W, Chambers WJ, Tabrizi MA, King J, Goetz R, Davies M, Stiller RL: Imipramine in prepubertal major depressive disorders. Arch Gen Psychiatry 44:81-89, 1987
34. Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, LaPierre YD, Masco HL, Mendels J: Antidepressant efficacy of sertraline: A double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 51 (12, Suppl B): 18-27, 1990
35. Riddle MA, Scahill L, King RA, Hardin MT, Anderson GM, Ort SI, Smith JC, Leckman JF, Cohen DJ: Double-blind crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 31:1062-1069, 1992
36. Ryan ND, Puig-Antich J, Rabinovich H, Fried J, Ambrosini P, Meyer V, Torres D, Dachille S, Mazzie D: MAOIs in adolescent major depression unresponsive to tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 27:755-758, 1988
37. Sabelesky DA: Fluoxetine in adults with residual attention deficit disorder and hypersomnolence. J Neuropsychiatry Clin Neurosci 2:463-164, 1990
38. Simeon JG, Ferguson HB, Van Wyck Fleet J: Bupropion effects in attention deficit and conduct disorders. Can J Psychiatry 31:581-585, 1986
39. Szatmari P, Offord DR, Boyle MH: Ontario Child Health Study: Prevalence of attention deficit disorder with hyperactivity. J Child Psychol Psychiatry 30:219-230, 1989
40. Tierney E, Joshi PT, Llinas JF, Rosenberg LA, Riddle MA: Sertraline for major depression in children and adolescents: Preliminary clinical experience. J Child Adolesc Psychopharmacol 5:13-27, 1995
41. Wender PH, Reimherr FW: Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry 147:1018-1020, 1990
42. Wender PH, Wood DR, Reimherr FW: Pharmacological treatment of attention deficit disorder, residual type (ADD,RT, "minimal brain dysfunction," "hyperactivity") in adults. Psychopharmacol Bull 21:222-231, 1985
43. Whitaker A, Johnson J, Shaffer D, Rapoport JL, Kalikow K, Walsh BT, Davies M, Braiman S, Dolinsky A: Uncommon troubles in young people: Prevalence estimates of selected psychiatric disorders in a nonreferred adolescent population. Arch Gen Psychiatry 47:487-496, 1990
44. Wilens TE, Biederman J, Geist DE, Steingard R, Spencer T: Nortriptyline in the treatment of ADHD: A chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 32:343-349, 1993
45. Wilens TE, Biederman J, Mick E, Spencer TJ: A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis 183:48-50, 1995
46. Wilens TE, Biederman J, Prince J, Spencer TJ, Faraone SV, Warburton R, Schleifer D, Harding M, Linehan C, Geller D: Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 153:1147-1153, 1996
47. Zametkin A, Rapoport JL, Murphy DL, Linnoila M, Ismond D: Treatment of hyperactive children with monoamine oxidase inhibitors: I. Clinical efficacy. Arch Gen Psychiatry 42:962-966, 1985